Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while ProShares UltraPro Short QQQ ETF trades at $38.81. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while ProShares UltraPro Short QQQ ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SQQQ | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $89.43 |
52-Week Low | $555.51 | $36.04 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SQQQ, a 3x leveraged inverse ETF tracking the Nasdaq-100, trades at $38.31, up 0.34% on the day. Technical indicators are predominantly bearish, with moving averages signaling sell and oscillators neutral. The ETF is designed to gain when the Nasdaq-100 declines, but its structure leads to value erosion over time due to daily resets. Recent news highlights its use as a tactical hedge amid tech sector volatility but warns of long-term unsuitability.
The outlook for SQQQ is highly speculative and short-term oriented. It may offer tactical gains if tech stocks weaken, but structural decay and high volatility pose significant risks. Investors should view it as a hedging tool rather than a long-term holding, with success dependent on precise market timing and active management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
